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A B S T R A C T
Despite the medical advances of the 21st century, the incidence of cancer continues to increase and the search for
a universal cure remains a major health challenge. Our lack of understanding the complex pathophysiology of
the tumor microenvironment has hindered the development and efficiency of anti-cancer therapeutic strategies.
The tumor microenvironment, composed of multiple cellular and non-cellular components, enables tumor-
promoting processes such as proliferation, angiogenesis, migration and invasion, metastasis, and drug resistance.
The ubiquitin-mediated degradation system is involved in several physiologic processes including cell cycling,
signal transduction, receptor downregulation, endocytosis and transcriptional regulation. Ubiquitination in-
cludes attachment of ubiquitin to target proteins via E1 (activating), E2 (conjugating) and E3 (ligating) enzymes.
Several studies have shown that E2 enzymes are dysregulated in variety of cancers. Multiple investigations have
demonstrated the involvement of E2s in various tumor-promoting processes including DNA repair, cell cycle
progression, apoptosis and oncogenic signaling. E2 enzymes consist of 40 members that facilitate ubiquitin-
substrate conjugation thereby modulating the stability and interaction of various proteins. As such, E2s are
potential biomarkers as diagnostic, prognostic and therapeutic tools. In this review, we discuss the role of E2s in
modulating various types of cancer.
1. Introduction
The uncontrolled proliferation of cells, which leads to rapid growth
of disorganized tumor tissue is known as cancer [1,2]. Cancer is one of
the main causes of mortality in developed countries, and the developing
world, to a lesser extent. Modified human lifestyles during the last
decades including physical inactivity, poor dietary habits and substance
abuse have increased cancer risks [3–6]. Accordingly, increased pre-
valence of colorectal, breast, lung, and prostate cancers has been ob-
served in developed countries. On the other hand, some infection-re-
lated cancers such as cervical, stomach, and liver cancers are increased
in less developed countries [7]. Multiple cellular and non-cellular
components are present in tumor region, which forms the tumor mi-
croenvironment [8,9]. The nature of the tumor microenvironment in
tumor progression and modulation of cancer immunotherapy has been
extensively demonstrated [10]. Several non-cancerous cellular partici-
pants form the tumor microenvironment including immune and in-
flammatory cells, bone marrow derived cells, cancer associated fibro-
blasts (CAFs), extracellular matrix, pericytes, and endothelial cells. The
interaction of cancer cells with this complex network enhances tumor
growth and progression and induces drug resistance [11,12]. The tumor
microenvironment can also promote the induction of cancer stem cells,
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which support tumor recurrence [13,14]. Although several efforts have
focused on understanding tumor immuno-biology and identifying new
therapeutic strategies, current treatments are unable to counter a
variety of tumour types. This is due partly to the ability of cancer cells
to outsmart anti-tumour mechanisms by both intrinsic tumour factors
and the extrinsic support of the tumor microenvironment (Fig. 1)
[15,16]. These intrinsic and extrinsic pressures promote tumor growth,
drug resistance, the development of cancer stem cells, cancer recur-
rence and metastasis. Intrinsic mechanisms, which are mainly fueled by
mutations, include dysregulated apoptosis, drug efflux, loss of specific
oncogenes, modified metabolism, development of stemness, and en-
hanced DNA repair. On the other hand, extrinsic pressure includes
several mechanisms driven by multiple cellular and non-cellular
components of the tumor microenvironment [17–21].
It has recently been shown that enzymes involved in ubiquitination,
which leads to proteasome-mediated protein degradation, are critically
involved in tumorigenesis. These enzymes include E1 (activating), E2
(conjugating), and E3 (ligating) enzymes, which facilitate ubiquitina-
tion. Amongst them, the E2-conjugating enzymes have been proposed
as pivotal factors, which are dysregulated in cancer settings and con-
tribute to various tumor-promoting processes including DNA repair,
apoptosis, cell cycle progression, and oncogenic signaling pathways.
Therefore, they can be considered as reliable prognostic and diagnostic
indicators, which can be targeted as part of a cancer therapeutic
strategy. In this review, we will discuss the intricacies of E2-conjugating
enzymes and their role in cancer progression.
Fig. 1. Schematic demonstration of the ubiquitination process. Following activation, ubiquitin binds to E1 in an ATP-dependent manner. It then binds to the E2
enzyme and subsequently interacts with substrate proteins through the activity of E3 ligases. The ubiquitinated target proteins are subsequently degraded by the 26S
proteasome complex
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2. UBE2s
The highly conserved protein, ubiquitin (UB; containing 76-amino
acids with a molecular weight of 8.5 kDa) is present in all eukaryotic
cells. UB can regulate the stability and biological functions of its sub-
strates by ubiquitination, whereby UB covalently conjugates with target
proteins in a reversible manner [22]. During ubiquitination, UB pro-
teins bind substrate proteins through the coordinated activity of three
enzymes: E1 (activating), E2 (conjugating) and E3 (ligating) enzymes.
For ubiquitination, UBE1-activating enzymes first bind and activate UB
via ATP consumption in order to form the E1-Ub conjugate. This is
followed by the UBE2-conjugation enzyme, which binds to a thioester
group of UB through the cysteine residue. The conjugation of specific
lysine residues of the protein substrate with glycine on UB is finally
facilitated by UBE3 ligases [23]. The class of isopeptidases, known as
deubiquitinases, can remove UB chains from substrate proteins [24].
Ubiquitination, as one of the most pivotal post-transcriptional me-
chanisms, plays a key role in multiple physiological processes [25].
Although ubiquitination has been known as protein degradation tool,
there is evidence that it contributes to various processes including
transcription, endocytosis, DNA repair, intracellular trafficking, plasma
membrane receptor recycling, angiogenesis and inflammatory signaling
[26]. This functional diversity may be partly due to presence of various
lysine residues (K) in UB including K6, 11, 27, 29, 33, 48, and 63, which
mediate formation of the polymeric chain [27]. Accordingly, dysregu-
lation of ubiquitination has been associated with several disorders such
as neurodegenerative diseases, autoimmune disorders, muscle atrophy,
diabetes, and cancer. Among the ubiquitination-involved enzymes, E2s
play a key role in various types of cancer and are comprised of four
different categories. Class I E2s have only the UBC domain, whereas
class II and III E2s contain additional N and C terminal domains, re-
spectively. Class IV E2s contain both N and C domains [28]. Table 1
shows the main E2 enzymes with their biological functions and asso-
ciated diseases (Fig. 2).
3. UBE2s in cancer
Several investigations have indicated that all ubiquitination-asso-
ciated enzymes including E1, E2, and E3 promote tumorigenesis, which
implies that they may be suitable targets for anti-cancer therapies.
However, the design and development of selective inhibitors, which can
block protein-protein interactions is problematic. Among the ubiquiti-
nation-associated enzymes, E2s have emerged as potent mediators of
tumorigenesis. The E2 family is comprised of 40 members, which
modulate the stability of proteins and ubiquitination through the con-
jugation of UB to target proteins [29]. Dysregulation of various E2s has
been reported in several cancer types. Moreover, multiple E2 enzymes
can drive cell cycle progression, DNA repair, and stimulation of onco-
genic signaling pathways during malignant transformation. Therefore,
E2s can be considered as worthy cancer related biomarkers for diag-
nosis, prognosis and therapeutic targeting. Despite advances in the
identification of the biological properties of E2 enzymes, a limited
number of E2-selective inhibitors have been developed [28,30].
3.1. UBE2A in cancer
UBE2A, a RAD6 yeast homolog HR6A protein, promotes cell cycle
progression by binding with the RAD18 ubiquitin ligase, which leads to
induction of poly-ubiquitination process. UBE2A is a critical factor in
tumorigenesis. Dysregulated expression of cyclin dependent kinases
(CDKs), which are key modulators of cell cycle, can affect UB protea-
somal degradation and trigger cancer induction [31,32]. Blockade of
UBE2A interaction with RAD18 has been identified as potential cancer
therapeutic strategy [33].
3.2. UBE2C in cancer
UBE2C, located at chromosome 20q13.12, consists of eight isoforms
with a molecular weight of 19 kDa and composed of 179 amino acids.
UBE2C is expressed variably during cell cycle progression, which cor-
relates with its role in cell cycle regulation [3]. UBE2C is also involved
in the regulation of mitosis and targeted degradation of short-lived
proteins [34]. The overexpression of UBE2C has been associated with
various cancer types, and correlates with poor prognosis and drug re-
sistance [35–38]. The overexpression of UBE2C by various cancer cell
lines compared to normal cells has been demonstrated [39]. Other in-
vestigations have demonstrated that UBE2C plays a role in the expan-
sion and invasion of cancer cells [40,41], with overexpression corre-
lating with poor prognosis of pancreas, lung, breast, skin and thyroid
cancers [3,41–45].
Increased expression of UBE2C has also been observed in tumours
compared to normal tissue of breast cancer patients [46], which was
associated with poor prognosis. However, no correlation between the
expression of UBE2C and the clinical manifestation of breast cancer
subtypes has been observed. UBE2C can also promote drug resistance in
cancer cells, as blockade of UBE2C led to enhanced breast cancer cell
sensitivity to doxorubicin [47]. Therefore, the expression of UBE2C can
serve as a biomarker of doxorubicin sensitivity in breast cancer pa-
tients.
BRCA1 can also act as a negative UBE2C regulator [48,49]. Ac-
cordingly, blockade of BRCA1 expression was associated with upregu-
lation of UBE2C. The interaction of BRCA1 with other UBE2s has also
been demonstrated [38].
The upregulation of UBE2C has also been associated with human
intestinal-type gastric cancer. Furthermore, silencing of UBE2C in these
cells correlated with the interruption of cell cycling at the G2/M stage.
On the other hand, overexpression of this enzyme led to enhanced ERK
signaling and proliferation of cancer cells. Interestingly, blockade of
ERK signaling by its inhibitor, U0126, reversed UBE2C-induced onco-
genic phenotypes. Overexpression of UBE2C induces chromosomal in-
stability, perturbs the cell cycle and indicates poor prognosis of gastric
cancer [3].
High expression levels of UBE2C have also been observed in hepa-
tocellular carcinoma, which was associated with advanced disease and
low survival rates. Consequently, silencing UBE2C led to reduced ex-
pansion, invasion, and migration of hepatocellular carcinoma cells. This
strategy also enhanced the sensitivity of these cells to cytotoxicity as-
sociated with chemotherapeutics such as 5-fluorouracil, Adriamycin,
and sorafenib. Therefore, UBE2C can also be considered as potential
prognosis factor and therapeutic target in hepatocellular carcinoma
[50].
It has been proposed that miR-495 regulates cisplatin resistance in
non-small cell lung cancer (NSCLC) partly by modulating UBE2C.
Moreover, lung cancer biopsies express low levels of miR-495. Higher
expression levels of UBE2C have also been observed in cisplatin-re-
sistant NSCLC cells, which was associated with high proliferation, in-
vasion and drug resistance. Accordingly, silencing UBE2C led to upre-
gulation of E-cadherin and downregulation of vimentin. UBE2C can
directly bind to the 5'-UTR of the genes that confer drug-resistance such
as ERCC1 and ABCG2. On the other hand, miR-495 can suppress ERCC1
and ABCG2 by regulating UBE2C. Therefore, the miR-495/UBE2C/
ERCC1/ABCG2 axis can suppress cisplatin resistance partly by ham-
pering epithelial to mesenchymal transition (EMT), and down-
regulating the expression of of drug resistance associated genes by
NSCLC cells [51].
Upregulation of UBE2C has also been detected in rectal carcinoma.
Moreover, silencing this factor by siRNA interference was associated
with cancer cell apoptosis and reduced proliferation, invasion, and
colony formation. Similarly, downregulation of UBE2C in a xenograft
tumor model led to tumor regression. Interestingly, miR-381 modulates
the expression of UBE2C in rectal carcinoma [52].
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Using immunohistochemical assays, it has been shown that ex-
pression levels of UBE2C protein are elevated in nasopharyngeal car-
cinoma tissues compared to benign nasopharyngeal tissues, which
correlated with tumor size and metastasis. Moreover, expression levels
of UBE2C negatively correlated with the degree of differentiation of
nasopharyngeal carcinoma cell lines. Furthermore, silencing UBE2C led
to cell cycle arrest at the S and G2/M phases and reduced proliferation
of undifferentiated C666-1 and poorly-differentiated CNE2Z nasophar-
yngeal carcinoma cells, but not immortalized NP-69 and well-differ-
entiated CNE1 cells. These observations imply that overexpression of
UBE2C in nasopharyngeal carcinoma is associated with cancer pro-
gression, which therefore makes UBE2C a suitable biomarker candidate
for the progression, diagnosis, and treatment of nasopharyngeal carci-
noma [53].
It has been suggested that evaluation of urinary UBE2C levels can be
used for discriminating patients with bladder cancer from normal
subjects with hematuria. Overexpression of UBE2C in bladder cancer is
associated with advanced tumors, shorter cancer-specific survival, poor
prognosis, and lymph vascular invasion [54]. The prognostic value of
UBE2C in bladder cancer has also been demonstrated in other studies
[55,56].
3.3. UBE2D1 in cancer
UBE2D consists of three main forms: UBE2D1, D2, and D3, which
share 88% sequence homology and a similar enzymatic function.
Dysregulation of UBE2D is involved in carcinogenesis as it promotes
ubiquitination of the p53 protein [57,58]. Accordingly, silencing
UBE2Ds upregulates p53, which is associated with increased apoptosis
of human lung cancer cells [59]. Moreover, UBE2D4 (also known as
HBUCE1) interacts with the E3 ubiquitin ligase CHIP and modulates
cell cycle activities and proliferation of cancer cells [60]. Thus, tar-
geting UBE2Ds can serve as a cancer immunotherapy strategy [61].
UBE2D1 can activate NF-kB and ubiquitinate stimulated receptor-
interacting protein 1 (RIP1) in a TNF-α and cellular inhibitor of
apoptosis protein 1 (c-IAP1)-dependent manner [62]. Blocking the in-
teraction between UBE2D1 and Smad ubiquitination regulatory factor 2
(SMURF2) stabilizes Kirsten Ras (KRAS) and decreases cancer cell
Table 1
Main ubiquitin E2 enzymes and their biological and pathological functions.
Name Classes Diseases Biological roles
UBE2A Class I Cancer
Cognitive disability
Skeletal
muscle atrophy
novel X-linked mental retardation (XLMR)
DNA repair
Transcription regulation
UBE2B Class I Idiopathic azoospermia
Skeletal muscle atrophy
DNA repair
Cell cycle progression Spermatogenesis
UBE2C Classes II Cancer Cell cycle progression
UBE2D1 Class I Cancer DNA repair
Iron transport
UBE2D2 Class I Parkinson disease DNA repair
Parkin mediated mitophagy
UBE2D3 Class I Parkinson disease Infectious disease DNA repair
NF-κB signaling
UBE2D4 Class I Cancer DNA repair
UBE2E1 Classes II Cancer
Sjogren’s syndrome
PTEN ubiquitination and transport
UBE2E2 Classes II Diabetes Glucose homeostasis
UBE2E3 Classes II Liddle’s syndrome NRF2 transport
Epithelial Na+ transport
UBE2F Classes II Cancer Protein neddylation
UBE2G1 Class I Skeletal muscle atrophy Skeletal muscle protein regulation
UBE2G2 Class I Cancer
Sjogren’s syndrome
ER-associated degradation (ERAD)
UBE2H Classes III Autism Histone and cytoskeleton ubiquitination
UBE2I Class I Cancer SUMO E2
UBE2J1 Classes III Sjogren’s syndrome
Skeletal muscle atrophy
ERAD
Spermiogenesis
UBE2J2 Classes III Cancer ERAD
UBE2K Classes III Huntington Disease Aggregate formation of expanded polyglutamine
UBE2L3 Classes I Lupus erythematosus and rheumatoid
arthritis
proteins
UBE2L6 Classes I Cancer NF-κB signaling
UBE2M Classes II Hypertension Protein neddylation
UBE2N Classes I Parkinson disease DNA repair
UBE2O Class IV Cancer
Microcytic anemia
AMPKα2 ubiquitination and degradation
MLL ubiquitination and Degradation Erythroid differentiation and proteostasis Adipocyte differentiation
Endocytic trafficking
UBE2Q1 Classes II Cancer β-catenin-EGFR-PI3K-AKT-mTOR signaling
UBE2Q2 Classes II Cancer
Chronic kidney disease
Apoptosis
UBE2R1 Classes III Parkinson disease Cell cycle progression
UBE2R2 Classes III Unknown β-catenin degradation
UBE2S Classes III Cancer
Parkinson disease
Cell cycle progression
UBE2T Classes III Cancer
Fanconi anemia
DNA repair
UBE2U Classes III Riddle’s syndrome DNA repair
UBE2W Classes I Fanconi anemia E2 for α-amino group ubiquitination
UBE2Z Class IV Coronary artery disease FAT10 conjugation
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development in vitro and in vivo [63]. Inactivation of p53 robustly af-
fects the development of lung adenocarcinoma [64]. UBE2Ds enhances
DNA repair [65] and hence neutralize the DNA-damaging effects of
chemotherapy or radiotherapy in cancer cells [66]. Accordingly, the
overexpression of UBE2D1 has been shown to correlate with poor
prognosis of lung adenocarcinoma [59].
Overexpression of UBE2D1 is also associated with recurrent
genomic copy number gain and upregulation of IL-6 in hepatocellular
carcinoma. Moreover, IL-6 robustly enhanced growth of hepatocellular
carcinoma partly by genomic gain of UBE2D1 and activation of the
DNA damage response [67].
3.4. UBE2E1 in cancer
UBE2E1 can modulate the expression of HOX through the ubiqui-
tination of histones [68]. Although the precise function of UBE2E1 is
unknown, its regulatory impact on HOX expression can serve as a
prognostic index for AML as dysregulation in the expression of HOX
genes has been observed in AML patients [69,70].
3.5. UBE2F in cancer
Activated protein neddylation occurs in various cancerss. However,
little is known regarding the role of UBE2F, a neddylation E2, in tu-
morigenesis. Overexpression of UBE2F has been observed in NSCLC,
which was associated with poor patient survival. Moreover, UBE2F
promotes cancer progression, which can be blocked by selective silen-
cing techniques. UBE2F also promotes NOXA ubiquitination and pro-
teasomal degradation by activating CRL5 (Cullin-RING-ligase-5)
through CUL5 neddylation in a UBE2F/SAG/CUL5-dependent manner.
Accordingly, the overexpression of UBE2F and CUL5 correlates with
downregulation of NOXA and poor survival of lung cancer patients.
These occurrences imply that UBE2F promotes lung cancer growth by
ubiquitination and degradation of NOXA via CRL5 and thereby could
serve as a cancer therapeutic target [71].
3.6. UBE2I in cancer
Activating mutations in the KRAS gene have been extensively ob-
served in various cancers [72]. UBE2I (small ubiquitin-like modifier
(SUMO) E2 ligase Ubc9) has been identified as KRAS lethal partner.
UBE2I can regulate the stability and function of various proteins [73].
SUMOylation is pivotal for responses to cellular stresses, including
genomic instability, DNA damage, and heat shock [74–76], indicating a
role for this pathway and UBE2I in cancer progression. Consequently,
targeting the SUMO pathway and UBE2I are potential therapeutic
strategies for KRAS mutant colorectal cancer [77].
3.7. UBE2J2 in cancer
UBE2J2 is localized in the endoplasmic reticulum, it responds to
proteotoxic stress and facilitates proteasomal degradation by inter-
acting with ubiquitin ligases, such as parkin, CHIP, and TEB4 [78].
UBE2J2 also promotes TNF-R2-induced ubiquitination and degradation
of TRAF2 through interaction with c-IAP1 [79]. UBE2J2 is involved in
cancer cell invasion. Accordingly, overexpression of UBE2J2 has been
detected in cell protrusions of HCCLM3 hepatocellular carcinoma cells
[80]. However, further studies are required to understand the specific
role(s) of UBE2J2 in promoting cancer progression.
3.8. UBE2L6 in cancer
The ubiquitin-like protein modifier, Interferon Stimulated Gene 15
(ISG15), can conjugate and regulate the function of protein substrates.
ISG15 can conjugate protein substrates through the consecutive activity
of E1, E2 and E3 enzymes. ISG15 and UBE2L6 have been identified as
negative regulators of autophagy in esophageal cancer cells, which
implies their involvement in cancer progression [81].
Fig. 2. NSAIDs, Natural products, TCM and metformin can activate AMPK. AMPK inhibits the mTOR pathway, leading to inhibition of cancer cell growth and
proliferation. It can also suppress the pro-inflammatory enzyme COX-2, which is also involved in tumorigenesis. AMPK can induce the phosphorylation of tumor
suppressor p53, resulting in cell cycle arrest. Activation of AMPK also enhances phosphorylation of ACC involved in metabolism of lipids. AMPK also prevents cancer
progression through the anti-Warburg effect, cell cycle arrest, and suppression of EMT. UBE2O also promotes cancer progression by targeting AMPKα2 for ubi-
quitination and degradation, leading to induction of the mTOR-HIF-1α pathway.
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3.9. UBE2O in cancer
UBE2O, which can exert both E2 and E3 ligase activities, is involved
in the endosomal trafficking of proteins [82], SMAD6 ubiquitination
[83], and the cytoplasmic detention of nuclear BAP1 [84]. Increased
expression of UBE2O has been demonstrated in various types of cancer
[85–89]. UBE2O promotes cancer progression by targeting the AMP-
activated protein kinase alpha 2 (AMPKα2) for ubiquitination and de-
gradation, which leads to induction of the mTOR-HIF-1α pathway. The
stability and function of AMPK are important factors in cancer. Con-
sequently, the expression and function of AMPK is decreased in multiple
cancers including kidney, breast, ovarian, and gastric cancers [90,91].
AMPK can suppress tumor progression by various mechanisms such as
inhibition of mTOR signaling, the anti-Warburg effect, cell cycle arrest,
and inhibition of EMT [92,93]. Therefore, inhibition of UBE2O can
suppress tumor development partly through the restoration of
AMPKα2, which indicates that targeting the AMPKα2/UBE2O pathway
can also serve as cancer therapeutic strategy [94].
IL-1 promotes the degradation of UBE2O and IRAK1/4 in normal
cells. On the other hand, MLLs are resistant to degradation because they
lack the MLL-UBE2O-binding site. Blockade of IRAK or UBE2O and
concomitant proliferation of MLL leukemia cells has also been de-
monstrated [95,96].
3.10. UBE2Q1 in cancer
Dysregulated expression of UBE2Q1 has been observed in several
cancers including breast, colorectal, hepatocellular and ALL [97]. Ac-
cordingly, higher UBE2Q1 levels have been detected in cancerous tis-
sues of hepatocellular carcinoma compared to adjacent normal tissues.
Moreover, upregulation of UBE2Q1 significantly correlated with ad-
vanced stages of hepatocellular carcinoma and poor prognosis. Upre-
gulated expression levels of UBE2Q1 were also detected in the serum of
patients with hepatocellular carcinoma. Consequently, silencing
UBE2Q1 by siRNA led to decreased proliferation, cell cycle arrest, and
upregulation of p53 and p21 in BEL-7404 and HepG2 cells [98].
It has been proposed that UBE2Q1 can bind and suppress p53 ex-
pressed by breast cancer cells. Accordingly, transfection of MDA-MB-
468 breast cancer cells with the UBE2Q1-containing vector pCMV6-AN-
GFP was associated with downregulation of p53 and concomitant re-
sistance to apoptosis. This indicates that UBE2Q1 increases the survival
of cancer cells partly by ubiquitination of p53 and proteasome de-
gradation [99].
Dysregulated expression of UBE2Q1 and UBE2Q2 has also been
detected in colorectal cancer. The existence of CpG motifs in the loci of
the UBE2Q1 and UBE2Q2 promoters, suggests that epigenetic changes
may affect their expression levels. Consequently, the evaluation of the
methylation status in the promoter regions of UBE2Q1 and UBE2Q2
genes expressed by tumor biopsies obtained from 60 patients with
colorectal cancer showed differential methylation of both genes in
cancer tissues compared to adjacent normal tissues. Results obtained
showed that the UBE2Q2 promoter had a more unmethylated allele,
whereas the UEBE2Q1promoter had more methylated allele in com-
parison to adjacent normal tissues [100].
3.11. UBE2Q2 in cancer
UBE2Q2, which is also known as UBCi, plays an important role in
the progression of various cancers including head and neck squamous
cell carcinoma. However, there is sparse knowledge regarding the
mechanism(s), which underlie UBE2Q2-induced tumour development.
The clue may lie in the expression of UBE2Q2 by human head and neck
carcinoma cell lines and tumor biopsies. Studies have shown that some
head and neck cancer (HNC) patients are resistant to CDDP (cis-dia-
mminedichloroplatinum) or docetaxesome, which are therapeutics ad-
ministered to HNC patients. Interestingly, the levels UBE2Q2 expressed
by resistant cell lines and tumor biopsies were low., Moreover, forced
expression of UBE2Q2 led reduced proliferation of cancer cells. These
results imply that UBE2Q2 acts as an onco-suppressor, which can im-
pact tumor growth and drug resistance. Consequently, UBE2Q2 can be
considered as a novel theranostic factor in head and neck squamous cell
carcinoma [101].
3.12. UBE2S in cancer
UBE2S is another E2 enzyme, which has been implicated in cancers
including lung, brain, colon, cervix, thyroid, liver, nasopharynx, and
breast cancer [102–105].
It has been demonstrated that silencing UBE2S in breast cancer cell
lines can affect their morphology, survival and proliferation. UBE2S
facilitates the exit of cells from the mitotic stage by the degradation of
substrate proteins by APC/C during mitosis via the proteasome
pathway. Silencing UBE2S by siRNA molecules in MDA-MB-231 and
BT20 (basal cell lines), and T47D and MCF7 cells (luminal cell lines) led
to suppressed proliferation, increased apoptosis and changed mor-
phology of cells, implying a role for UBE2S in tumorigenesis [106].
UBE2S can promote endometrial cancer through the UBE2S/SOX6/
β-Catenin pathway. Consequently the overexpression of UBE2S can
enhance the migration and expansion of endometrial cancer cells, while
silencing it reverses these effects. It has been observed that the upre-
gulation of UBE2S in endometrial cancer cells promotes nuclear trans-
location of β-Catenin through suppression of SOX6 and upregulation of
cyclin D1 and c-Myc. On the other hand, blockade of β-Catenin resulted
in the inhibition of UBE2S-induced cancer cell expansion. Therefore,
the components of the UBE2S-SOX6/β-Catenin axis can serve as prog-
nostic biomarkers and therapeutic targets of endometrial cancer [107].
Overexpression of UBE2S has also been observed in A549 lung
adenocarcinoma cells, the lung cancer cell lines H1975, H1299, and95D
and human lung cancer tissues, which was associated with poor prog-
nosis. Knockdown of UBE2S in lung cancer cells correlated with re-
duced colony formation and proliferation, and increased apoptosis.
UBE2S can regulate the expression of several genes involved in lung
cancer, particularly p53 protein. Moreover, UBE2S can critically affect
the growth and development of lung cancer [108].
Increased expression levels of UBE2S have been observed in highly
invasive A431-III cells in comparison to A431-P, which negatively
correlated with von Hippel-Lindau (VHL) and positively with HIF-1α.
Silencing or overexpression of UBE2S demonstrated that it enhances the
invasive and migratory characteristics of cancer cells via EMT signaling.
Moreover, expression of UBE2S is significantly suppressed by luteolin
and quercetin. These observations imply that UBE2S is involved in
cervical cancer cell invasion and partly by HIF-1α signaling, which can
be blocked by luteolin and quercetin [4].
UBE2S can also serve as a prognostic factor of hepatocellular car-
cinoma as it contributes to tumorigenesis partly by the proteasomal
degradation of p53. Consequently, overexpression of UBE2S enhanced
the proliferation and migration of cancer cells, while silencing it in-
hibited these characteristics by targeting p53. On the other hand, the
downregulation of UBE2S increased the expression of p53, p21 and
cyclin D1 thereby suppressing cell proliferation. Therefore, UBE2S may
be considered as an independent prognostic biomarker of hepatocel-
lular carcinoma [109].
UBE2S increases the stability and cellular accumulation of β-
Catenin by inhibiting its destruction. Moreover, UBE2S can enhance
colorectal tumorigenesis in vitro and in vivo. Therefore, UBE2S promotes
the malignancy of colorectal cancer by activating the Wnt/β-Catenin
signaling pathway [110].
3.13. UBE2T in cancer
UBE2T, which is also known as HSPC150, plays a key role in cell
proliferation and the maintenance of chromosome stability through the
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ubiquitination of FANCD2. UBE2T implements a self-inactivation
mono-ubiquitination process which can potentially induce negative
regulation [111]. UBE2T is overexpressed in prostate cancer, promotes
EMT and correlates with poor prognosis. It can enhance the prolifera-
tion, invasion and migration of cancer cells and promote tumor growth.
Furthermore, the expression of UBE2T directly correlated with vi-
mentin expression in prostate cancer [112]. Dysregulated expression of
UBET2 has also been detected in prostate, lung, and bladder cancers
[113,114]. Furthermore, UBE2T is located on chromosome 1q32.1;
characteristic of several cancers, which indicates the oncogenic nature
of this factor [115–118]. Hypoxia can reduce the expression UBE2T by
cancer cell lines resulting in sensitization to chemotherapeutics, which
further confirms the oncogenic potential of this factor [119]. The tumor
induction by UBE2T has also been observed in nasopharyngeal carci-
noma, by activation of the AKT/GSK3β/β-catenin pathway [120]. The
pro-tumor potential of UBE2T in hepatocellular carcinoma has been
linked to the ubiquitination of p53 [121]. The correlation between
UBE2T expression with poor clinical outcome has also been observed in
multiple myeloma [122], melanoma [123], lung and breast cancer
[124]. The overexpression of UBE2T has also detected in gastric tumor
tissues, which correlated with poor prognosis [125]. In addition, ubi-
quitin-proteasome can affect gastric cancer by modulating the expres-
sion of oncogenes, tumor suppressor genes, and various signaling
pathways [111].
Similar to other cancers, silencing UBE2T in osteosarcoma cells
resulted in suppressed invasion, proliferation, and migration of cancer
cells in a PI3K/Akt-dependent manner [126]. Knockdown of UBE2T
also induced similar results in bladder [127] and gastric [128] cancer.
Hao and colleagues have demonstrated that UBE2T is overexpressed
by lung cancer cell lines and biopsies from lung cancer patients, which
was associated with poor prognosis [129]. The involvement of UBE2T
in breast cancer progression through the interaction with BRCA1/
BARD1 complex and downregulation of BRCA1 has also been demon-
strated [130]. This is mirrored by the dysregulated expression of UBE2T
in breast cancer patients [131].
4. Conclusion
Despite several advances in the understanding of tumor im-
munobiology and the immunotherapy revolution, cancer treatment
remains a major health challenge [132]. There are several hurdles in
the journey to achieving an effective anti-cancer therapy [132,133].
The tumor microenvironment plays an important role in this predica-
ment as it habours multiple cellular and non-cellular components which
support tumor growth and suppress anti-tumor responses [132]. Ubi-
quitination, which is a hallmark of protein-degradation, has been
identified as a pivotal factor involved in several functions such as DNA
repair, transcription, recycling of cell membrane receptors, intracellular
trafficking, endocytosis, angiogenesis and inflammatory signaling.
Hence it is not surprising that their versatility corresponds with their
ability to induce tumour formation and progression [30,57,91,94,121].
Amongst the ubiquitination-associated enzymes, E2s play a key role in
carcinogenesis. This notion has been supported by various studies, in
which high levels of various E2 enzymes have been observed in mul-
tiple cancers such as breast, colon, bladder, hepatocellular carcinoma,
gastric, lung, cervix, nasopharyngeal carcinoma, and multiple myeloma
[3,41,45,55,91,101,123]. E2 enzymes can promote tumorigenesis by
different mechanisms. Furthermore, silencing their expression facil-
itates the suppression of cancer growth and development. Although
these results substantiate their tumor-inducing properties, very few
studies have targeted these factors in pre-clinical models. Moreover,
data demonstrating the targeting of E2s in human cancer patients is
sparse. There are a few E2 inhibitors available such as the Peptoid
compound (Leucettamol A), Dimeric sterols (Manado sterols A and B),
NSC697923, CC0651, and Triazines compounds [30], however, their
specific functions and efficiency have not been demonstrated in human
cancers. Nano-based drug delivery systems are promising tools for
tumor-specific silencing of E2 enzymes, which should be considered in
future studies [134–136]. Thus, further studies based on the develop-
ment of potent anti-E2 therapeutics, are required to evaluate their ef-
ficacy as a cancer immunotherapy strategy.
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